On October 3, 2024, the US Food and Drug Administration (FDA) approved a new perioperative treatment (treatment that occurs before and after surgery) for non-small cell lung cancer (NSCLC). This combination approach involves being treated with a type of immunotherapy—called nivolumab (Opdivo®)—plus chemotherapy before surgery followed by nivolumab after surgery. This FDA approval applies to patients living with NSCLC that is resectable (able to be removed by surgery.) Read more about the approval here.
On September 19, the FDA approved amivantamab-vmjw (Rybrevant®) in combination with standard of care chemotherapy (carboplatin and pemetrexed) for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions (ex19del) or L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor (TKI). Read more here.
On September 25, the FDA approved osimertinib (Tagrisso) for adults with unresectable stage III non-small cell lung cancer (NSCLC) whose cancer has not progressed during or following chemoradiation and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as confirmed with an FDA-approved test. The approval was based on the LAURA study, which found that participants receiving osimertinib (Tagrisso) went longer until their disease progressed (known as progression-free survival, or PFS) compared to individuals receiving the placebo. You can learn more about this latest approval here.